ABCB5 Ligands and Substrates for PIP2 Pathway Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies fail to consistently eradicate malignant tumors due to the presence of cancer stem cells (CSCs) expressing ABCB5, which confer drug resistance and promote tumor progression and therapeutic resistance through the ABCB5-PIP2 pathway.
Innovation Solution
Modulating ABCB5-PIP2 pathway activity using PIP2 agonists or antagonists, such as phospholipids or anti-ABCB5 antibodies, to enhance or inhibit ABCB5-positive cell functions, including promoting wound healing and tissue regeneration, or inhibiting cancer cell functions like drug resistance and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ABCB5-PIP2 pathway is activated in cancer stem cells, then drug resistance and tumor progression are enhanced, but therapeutic efficacy is reduced
Solution Approach 1:
The patent extracts and targets the ABCB5-PIP2 pathway specifically in cancer stem cells using PIP2 antagonists that bind to the ABCB5 receptor, separating the harmful drug resistance function from the overall tumor mass. This selective extraction allows therapy to focus on eliminating the resistant stem cell population without affecting differentiated cells.
Solution Approach 2:
The patent introduces PIP2 antagonists as intermediary molecules that mediate the interaction between therapeutic agents and ABCB5-positive cancer stem cells. These antagonists block the ABCB5-PIP2 pathway, serving as a bridge that enables chemotherapy to effectively target and eliminate resistant stem cells while maintaining sensitivity to treatment.
2Reliability
If ABCB5-PIP2 pathway is inhibited in cancer cells, then therapeutic resistance is overcome, but normal tissue regeneration may be impaired
Solution Approach 1:
The patent applies local quality by differentiating between ABCB5-positive cancer stem cells and normal ABCB5-positive stem cells. The PIP2 antagonists are designed to selectively inhibit the pathway in cancer cells while preserving normal tissue regeneration functions, achieving localized therapeutic effect without systemic harm to regenerative processes.
Solution Approach 2:
The patent employs preliminary action by identifying and targeting ABCB5-positive cancer stem cells before they can establish therapeutic resistance. By intervening early in the pathway activation, the treatment prevents resistance development while allowing normal tissue regeneration to proceed uninterrupted.
3Reliability
If PIP2 antagonists are administered to block ABCB5-PIP2 pathway, then cancer stem cell function is inhibited, but off-target effects may occur
Solution Approach 1:
The patent incorporates feedback mechanisms through the development of PIP2 antagonists that specifically target the ABCB5-PIP2 interaction. The antagonists provide feedback control by binding to ABCB5 and preventing PIP2 activation, allowing for precise regulation of cancer stem cell inhibition while minimizing off-target effects through selective pathway blocking.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances ABCB5-positive cell functions in healthy subjects and inhibits cancer cell functions, effectively promoting wound healing and tissue regeneration while sensitizing cancer cells to chemotherapy, thereby overcoming therapeutic resistance.
Implementation Method 1
ABCB5 serves as a receptor for PIP2 and, to a lesser degree, PIP1 and PIP3
Implementation Method 2
The scaffolds may be seeded with cells, such as primary cells or stem cells, and various factors to encourage tissue growth
Data Source
AI summary
The present invention is directed to methods and compositions for modulating ABCB5+ stem cell activity. The invention also relates to assays and reagents for manipulating and characterizing compounds that modulate ABCB5+ cell signaling.